BI COPD fixed-dose combo under FDA review
This article was originally published in Scrip
Executive Summary
Seeking to grow its already successful chronic obstructive pulmonary disease (COPD) product line, Boehringer Ingelheim on 19 August revealed the FDA had accepted for review the new drug application (NDA) for the firm's fixed-dose combination (FDC) of tiotropium and olodaterol, which is intended to be delivered with the company's Respimat inhaler.